A Randomised Open-label Phase II Trial of Consolidation with Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy.

Trial Profile

A Randomised Open-label Phase II Trial of Consolidation with Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms STIMULI
  • Most Recent Events

    • 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress.
    • 07 Oct 2015 New drug added in the trial (Nivolumab) as reported by ClinicalTrials.gov record.
    • 07 Oct 2015 Planned End Date changed from 1 Apr 2020 to 1 Jan 2022 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top